240 related articles for article (PubMed ID: 38411576)
1. Highly effective cystic fibrosis transmembrane conductance (regulator) modulator therapy: shifting the curve for most while leaving some further behind.
Chun SW; Somers ME; Burgener EB
Curr Opin Pediatr; 2024 Jun; 36(3):290-295. PubMed ID: 38411576
[TBL] [Abstract][Full Text] [Related]
2. Corrector therapies (with or without potentiators) for people with cystic fibrosis with class II CFTR gene variants (most commonly F508del).
Southern KW; Murphy J; Sinha IP; Nevitt SJ
Cochrane Database Syst Rev; 2020 Dec; 12(12):CD010966. PubMed ID: 33331662
[TBL] [Abstract][Full Text] [Related]
3. Patients eligible for modulator drugs: Data from cystic fibrosis registry of Turkey.
Çobanoğlu N; Özçelik U; Çakır E; Şişmanlar Eyüboğlu T; Pekcan S; Cinel G; Yalçın E; Kiper N; Emiralioğlu N; Şen V; Şen HS; Ercan Ö; Çokuğraş H; Kılınç AA; Al Shadfan LM; Yazan H; Altıntaş DU; Karagöz D; Demir E; Kartal Öztürk G; Bingöl A; Başaran AE; Sapan N; Çekiç Ş; Çelebioğlu E; Aslan AT; Gürsoy TR; Tuğcu G; Özdemir A; Harmancı K; Yıldırım GK; Köse M; Hangül M; Tamay Z; Süleyman A; Yüksel H; Yılmaz Ö; Özcan G; Topal E; Can D; Korkmaz Ekren P; Çaltepe G; Kılıç M; Özdoğan Ş; Doğru D
Pediatr Pulmonol; 2020 Sep; 55(9):2302-2306. PubMed ID: 32453906
[TBL] [Abstract][Full Text] [Related]
4. Elexacaftor/Tezacaftor/Ivacaftor therapy in cystic fibrosis children previously CFSPID: Is it over-medicalization?
Terlizzi V
J Cyst Fibros; 2024 Mar; 23(2):366-367. PubMed ID: 37838487
[No Abstract] [Full Text] [Related]
5. Triple Therapy for Cystic Fibrosis
Barry PJ; Mall MA; Álvarez A; Colombo C; de Winter-de Groot KM; Fajac I; McBennett KA; McKone EF; Ramsey BW; Sutharsan S; Taylor-Cousar JL; Tullis E; Ahluwalia N; Jun LS; Moskowitz SM; Prieto-Centurion V; Tian S; Waltz D; Xuan F; Zhang Y; Rowe SM; Polineni D;
N Engl J Med; 2021 Aug; 385(9):815-825. PubMed ID: 34437784
[TBL] [Abstract][Full Text] [Related]
6. VX-445-Tezacaftor-Ivacaftor in Patients with Cystic Fibrosis and One or Two Phe508del Alleles.
Keating D; Marigowda G; Burr L; Daines C; Mall MA; McKone EF; Ramsey BW; Rowe SM; Sass LA; Tullis E; McKee CM; Moskowitz SM; Robertson S; Savage J; Simard C; Van Goor F; Waltz D; Xuan F; Young T; Taylor-Cousar JL;
N Engl J Med; 2018 Oct; 379(17):1612-1620. PubMed ID: 30334692
[TBL] [Abstract][Full Text] [Related]
7. Cystic fibrosis transmembrane conductance regulator modulators for cystic fibrosis: a new dawn?
Edmondson C; Course CW; Doull I
Arch Dis Child; 2021 Oct; 106(10):941-945. PubMed ID: 33785533
[TBL] [Abstract][Full Text] [Related]
8. The march towards CFTR modulator access for all people with CF: The end of the beginning.
VanDevanter DR
J Cyst Fibros; 2021 Mar; 20(2):185-187. PubMed ID: 33495080
[No Abstract] [Full Text] [Related]
9. Persistence and evolution of
Armbruster CR; Hilliam YK; Zemke AC; Atteih S; Marshall CW; Moore J; Koirala J; Krainz L; Gaston JR; Lee SE; Cooper VS; Bomberger JM
mBio; 2024 May; 15(5):e0051924. PubMed ID: 38564694
[TBL] [Abstract][Full Text] [Related]
10. VX-659-Tezacaftor-Ivacaftor in Patients with Cystic Fibrosis and One or Two Phe508del Alleles.
Davies JC; Moskowitz SM; Brown C; Horsley A; Mall MA; McKone EF; Plant BJ; Prais D; Ramsey BW; Taylor-Cousar JL; Tullis E; Uluer A; McKee CM; Robertson S; Shilling RA; Simard C; Van Goor F; Waltz D; Xuan F; Young T; Rowe SM;
N Engl J Med; 2018 Oct; 379(17):1599-1611. PubMed ID: 30334693
[TBL] [Abstract][Full Text] [Related]
11. Cystic fibrosis transmembrane conductance receptor modulator therapy in cystic fibrosis, an update.
Egan ME
Curr Opin Pediatr; 2020 Jun; 32(3):384-388. PubMed ID: 32374578
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and safety of elexacaftor plus tezacaftor plus ivacaftor versus tezacaftor plus ivacaftor in people with cystic fibrosis homozygous for F508del-CFTR: a 24-week, multicentre, randomised, double-blind, active-controlled, phase 3b trial.
Sutharsan S; McKone EF; Downey DG; Duckers J; MacGregor G; Tullis E; Van Braeckel E; Wainwright CE; Watson D; Ahluwalia N; Bruinsma BG; Harris C; Lam AP; Lou Y; Moskowitz SM; Tian S; Yuan J; Waltz D; Mall MA;
Lancet Respir Med; 2022 Mar; 10(3):267-277. PubMed ID: 34942085
[TBL] [Abstract][Full Text] [Related]
13. Elexacaftor/tezacaftor/ivacaftor (Trikafta) for cystic fibrosis.
Med Lett Drugs Ther; 2020 Jan; 62(1589):5-7. PubMed ID: 31999662
[No Abstract] [Full Text] [Related]
14. Development of elexacaftor - tezacaftor - ivacaftor: Highly effective CFTR modulation for the majority of people with Cystic Fibrosis.
Middleton PG; Taylor-Cousar JL
Expert Rev Respir Med; 2021 Jun; 15(6):723-735. PubMed ID: 33249928
[No Abstract] [Full Text] [Related]
15. Cystic Fibrosis Transmembrane Conductance Regulator Modulator Therapy: A Review for the Otolaryngologist.
Lee SE; Farzal Z; Daniels MLA; Thorp BD; Zanation AM; Senior BA; Ebert CS; Kimple AJ
Am J Rhinol Allergy; 2020 Jul; 34(4):573-580. PubMed ID: 32168995
[TBL] [Abstract][Full Text] [Related]
16. Ethical Dilemma: Elexacaftor-Tezacaftor-Ivacaftor or Lung Transplantation in Cystic Fibrosis and End-Stage Lung Disease?
Breuer O; Shoseyov D; Koretz S; Alyan N; Reiter J; Cohen-Cymberknoh M; Wexler I; Kerem E
Chest; 2022 Mar; 161(3):773-780. PubMed ID: 34506793
[TBL] [Abstract][Full Text] [Related]
17. CFTR modulator use in post lung transplant recipients.
Benninger LA; Trillo C; Lascano J
J Heart Lung Transplant; 2021 Dec; 40(12):1498-1501. PubMed ID: 34538541
[TBL] [Abstract][Full Text] [Related]
18. New Drug Hailed as Major Breakthrough in Cystic Fibrosis.
Am J Med Genet A; 2020 Jan; 182(1):8-9. PubMed ID: 31825178
[No Abstract] [Full Text] [Related]
19. Immunosuppressant management upon elexacaftor/tezacaftor/ivacaftor initiation in cystic fibrosis patients with prior liver transplant.
Coman D; Vincent C; Huard G; Marleau D; Lavoie A; Hercun J
J Cyst Fibros; 2024 May; 23(3):561-562. PubMed ID: 38000917
[No Abstract] [Full Text] [Related]
20. Clinical Effectiveness of Elexacaftor/Tezacaftor/Ivacaftor in People with Cystic Fibrosis: A Clinical Trial.
Nichols DP; Paynter AC; Heltshe SL; Donaldson SH; Frederick CA; Freedman SD; Gelfond D; Hoffman LR; Kelly A; Narkewicz MR; Pittman JE; Ratjen F; Rosenfeld M; Sagel SD; Schwarzenberg SJ; Singh PK; Solomon GM; Stalvey MS; Clancy JP; Kirby S; Van Dalfsen JM; Kloster MH; Rowe SM;
Am J Respir Crit Care Med; 2022 Mar; 205(5):529-539. PubMed ID: 34784492
[No Abstract] [Full Text] [Related]
[Next] [New Search]
